First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Incyte Corporation

    INCY · 3 developments mapped · last assessed 2026-09-06

    Market Ontology has mapped 3 macro, policy, and market developments to Incyte Corporation since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for INCY yet, so no modelled value is shown. The INCY valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run INCY on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for INCY. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics

      Increased market opportunity for Opzelura (ruxolitinib cream), a topical JAK inhibitor for atopic dermatitis. While topical, it benefits from the overall market expansion and increased awareness of JAK inhibitors.

      · Moves revenue growth rate, market share assumptions

    • Open question

      Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand

      Increased demand for Opzelura (ruxolitinib cream), a topical JAK inhibitor for atopic dermatitis, contributing to dermatology segment revenue.

      · Moves revenue growth rate, product pipeline success

    What changed, by assumption

    Revenue growth rate
    • 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
    • 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
    Market share for jakafi (ruxolitinib)
    • 2026-09-01Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-06-22MarginBullishSettlement with CMS regarding Medicaid rebate rules for Opzelura results in a $246M one-time non-cash benefit and improved gross-to-net margins going forward.1.00

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics DemandBullish1-5y0.40
    2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicsBullish3-12m0.60
    2026-09-01Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHOwatch1-3m0.20